Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Northwest Biotherapeutics Inc. -- Ignore unavailable to you. Want to Upgrade?

To: John McCarthy who wrote (53)	8/22/2006 8:03:04 PM
From: zeta1961	Read Replies (1) \| Respond to of 760

John, I did a search at ASCO using the primary author's name and it brought up an abstract from June 2006..you'll note that there is no company attributed in this paper..to be honest and not catty;-)...I think the data could be stronger to really wow me...imo, NWB's data is much better..bwdik? I have a feeling, after reading the full text of NWB's P1, that manufacturing will have to be dealt with and it won't be real easy..I plan to have a bundle of shares in the LTBH column and more in the short-term column.. I imagine they are contantly pitching this vacine to whoever will listen..they better be!...No rush for data and information retrieval..this is a pet project at this point...Best and always a pleasure John..I hope that we never need the services of these wonderful cutting edge treatments..Elisabeth Tumor-specific peptide vaccination in newly-diagnosed patients with GBM. Sub-category: Vaccines Category: Developmental Therapeutics: Immunotherapy Meeting: 2006 ASCO Annual Meeting Printer Friendly E-Mail Article Abstract No: 2529 Citation: Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 2529 Author(s): A. B. Heimberger, S. F. Hussain, K. Aldape, R. Sawaya, G. A. Archer, H. Friedman, D. Reardon, A. Friedman, D. D. Bigner, J. H. Sampson Abstract: Background: Despite multimodality approaches, survival with GBM is dismal. Induction of immune responses to suppress the infiltrative, residual component with an easily manufactured and administered immunotherapy has been a theoretical ideal. The epidermal growth factor receptor variant III (EGFRvIII) is a tumor-specific cell surface protein expressed on approximately 40% of GBMs. Methods: Newly-diagnosed GBM patients with a gross-total resection, a KPS >70, and EGFRvIII+, after undergoing radiation with concurrent temozolomide without tumor progression, were eligible to receive EGFRvIII peptide vaccination i.d. with GM-CSF. Primary endpoint was safety. Results: Accrual began in 06/14/2004 and is now complete. 19 patients were enrolled. Median follow-up is 18 months. Toxicity was minimal and without evidence of autoimmunity. Humoral and cellular immune responses were generated. Median TTP from surgery in vaccine-treated patients is 12 months (n = 12), comparing favorably with a historical matched unvaccinated cohort (gross total resection without progression during radiation, KPS>70, EGFRvIII+) that had a median TTP of 7.1 months (n = 39) (p = 0.0058). These results also compared favorably with those reported for concurrent temozolomide and radiation followed by adjuvant temozolomide, with a median TTP of 6.9 months. Median survival in this trial has exceeded 18 months which compares favorably to all published analyses accounting for all known prognostic indicators. Among recurrent tumors evaluated by immunohistochemistry, 100% no longer expressed the EGFRvIII, suggesting immunological activation that eliminated EGFRvIII-expressing cells, as well as one potential mechanism of treatment failure. Conclusions: EGFRvIII peptide vaccination warrants further investigation in a larger randomized clinical trial in patients with EGFRvIII-expressing tumors.